A5058828484- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Transplantation: Methods and Outcomes
- Renal Transplantation Outcomes and Treatments
- Heart Failure Treatment and Management
- Cardiac Arrest and Resuscitation
- Atrial Fibrillation Management and Outcomes
- Cardiac pacing and defibrillation studies
- Viral Infections and Immunology Research
- COVID-19 Clinical Research Studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Fuel Cells and Related Materials
- Pharmaceutical Practices and Patient Outcomes
- Pneumocystis jirovecii pneumonia detection and treatment
- Acute Myocardial Infarction Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cytomegalovirus and herpesvirus research
- Venous Thromboembolism Diagnosis and Management
- SARS-CoV-2 and COVID-19 Research
- Dialysis and Renal Disease Management
- Antibiotics Pharmacokinetics and Efficacy
- Organ Transplantation Techniques and Outcomes
- Cardiac electrophysiology and arrhythmias
- Potassium and Related Disorders
- Chronic Kidney Disease and Diabetes
Texas Health Dallas
2016-2024
NewYork–Presbyterian Hospital
2015-2024
Columbia University
2016-2024
Long Island University
2019-2024
New York Hospital Queens
2015-2024
Columbia University Irving Medical Center
2015-2024
American College of Clinical Pharmacy
2023
Presbyterian Hospital
2018-2022
University of Kentucky
2022
Hartford Financial Services (United States)
2020
Nirmatrelvir/ritonavir (NR) use has not yet been described in solid organ transplant recipients (SOTRs) with mild COVID-19. The objective was to evaluate outcomes among SOTR and describe the drug-drug interaction of NR. This is an IRB-approved, retrospective study all adult on a calcineurin inhibitor (CNI) or mammalian target rapamycin who were prescribed NR between December 28, 2021 January 6, 2022. A total 25 included (n = 21 tacrolimus, n 4 cyclosporine, 3 everolimus, 1 sirolimus). All...
Treatment outcomes associated with the use of novel COVID-19 therapeutics in solid organ transplant recipients (SOTR) are not well described literature. The objective this analysis was to characterize 30-day hospitalization and other key secondary endpoints experienced by outpatient SOTR mild-moderate treated nirmatrelvir/ritonavir (NR), sotrovimab, or no SARS-CoV-2 specific treatment. This IRB-approved, retrospective study included 154 a documented positive infection between December 16,...
In recent years, there have been significant advancements in the understanding, risk-stratification, and treatment of cardiogenic shock (CS). Despite improved pharmacologic device-based therapies for CS, short-term mortality remains as high 50%. Most efforts research focused on CS related to acute myocardial infarction, even though heart failure (HF-CS) accounts >50% cases. There is a paucity high-quality evidence support standardized clinical practices approach HF-CS. addition, an unmet...
Journal Article Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma Get access Lisa E. Dumkow, Pharm.D., Pharm.D. Postgraduate Year 1 Pharmacy Resident, Department Services Henry Ford Hospital (HFH), Detroit, MI. Search for other works by this author on: Oxford Academic Google Scholar Johnathan R. Voss, B.S., B.S. Professional 4 pharmacy student Wayne State University/HFH. Michael Peters, B.S.Pharm., BCPS, BCPS Critical Care Specialist...
This retrospective cohort study evaluates the effect of chronic antimicrobial suppression (CAS) therapy on clinical outcomes in patients with continuous-flow left ventricular assist devices (CF-LVADs) and a history device-related infection. Patients CF-LVAD implantation between January 2008 August 2011 who received systemic CAS after index antibiotic treatment infection were included. Chronic was defined as continuation antibiotics for longer than 6 weeks Standard International Society Heart...
HLA antibodies pose a significant barrier to transplantation and current strategies reduce allosensitization are limited. We hypothesized that augmenting proteasome inhibitor (PI) based desensitization with costimulation blockade (belatacept) mitigate germinal center (GC) responses might increase efficacy prevent rebound. Four highly sensitized (calculated panel reactive antibody [cPRA] class I and/or II >99%, complement-dependent cytotoxicity [CDC PRA+], C1q+) heart transplant candidates...
Background— Renal failure requiring renal replacement therapy (RRT) has detrimental effects on quality of life and survival patients with continuous-flow left ventricular assist devices (CF-LVADs). Current guidelines do not offer a decision-making algorithm for CF-LVAD candidates poor baseline function. Objective this study was to identify risk factors associated RRT after implantation. Methods Results— Three hundred eighty-nine consecutive underwent contemporary implantation at the Columbia...
Objectives . To characterize anticoagulation practices with the Impella percutaneous ventricular assist device (pVAD). Background Managing in patients being supported by pVAD is made challenging several unique features of device. These include release a dextrose-based purge solution containing unfractionated heparin (UFH), need to concurrently administer systemic intravenous UFH, and lack an alternative strategy contraindications UFH. Methods pVAD, we conducted survey centers United States...
Driveline infection (DLI) is common after left ventricular assist device (LVAD). Limited data exist on DLI prevention and management. We investigated the impact of standardized driveline care initiatives, specific pathogens, chronic antibiotic suppression (CAS) outcomes. 591 LVAD patients were retrospectively categorized based initiatives implemented at our institution (2009-2019). Era (E)1: nonstandardized care; E2: protocol; E3: addition marking exit site; E4: "no shower" policy. 87(15%)...